A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non-small cell lung cancer cases

Lisa M. Rooper, Olga Nikolskaia, Jamal H. Carter, Yi Ning, Ming Tseh Lin, Zahra Maleki

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Summary Targeted therapies for pulmonary adenocarcinoma (ACA) necessitate specific subtyping and molecular testing of non-small cell lung carcinomas (NSCLC). However, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has decreased the tissue available for these assessments. While EBUS-TBNA specimens have previously been reported to successfully subtype NSCLC, allow immunohistochemistry (IHC), and support molecular diagnostics, no studies have documented the extent to which all objectives are possible in a single sample. Of 107 consecutive EBUS-TBNA specimens that were eligible for molecular testing, 98.8% had enough tissue for IHC, 80.2% received a definitive subtype, and 71.0% had both sufficient tissue to attempt molecular testing and technical success on multigene next-generation sequencing and ALK fluorescence in situ hybridization assays. Both subtyping and molecular diagnostics were possible in 57.9% of patients. The mean number of immunostains performed did not differ between patients with or without successful molecular testing (4.4 versus 4.6, P =.88). Only 40% of patients with insufficient tissue underwent repeat sampling. These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC, performing IHC, and completing multiple gene analyses. Although priorities must be assessed for each case individually, performance of IHC does not detract from completion of molecular diagnostics in general. Because most patients never undergo repeat sampling, the tissue yield of EBUS-TBNA should be improved to maximize evaluation for targeted therapies.

Original languageEnglish (US)
Pages (from-to)139-145
Number of pages7
JournalHuman Pathology
Volume51
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Needles
Coloring Agents
Molecular Pathology
Immunohistochemistry
Genes
Fluorescence In Situ Hybridization
Lung
Therapeutics

Keywords

  • Adequacy
  • Cytology
  • EBUS-TBNA
  • Immunohistochemistry
  • Molecular diagnostics
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non-small cell lung cancer cases. / Rooper, Lisa M.; Nikolskaia, Olga; Carter, Jamal H.; Ning, Yi; Lin, Ming Tseh; Maleki, Zahra.

In: Human Pathology, Vol. 51, 01.05.2016, p. 139-145.

Research output: Contribution to journalArticle

@article{98723ef277304082962b7aa009d91a02,
title = "A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non-small cell lung cancer cases",
abstract = "Summary Targeted therapies for pulmonary adenocarcinoma (ACA) necessitate specific subtyping and molecular testing of non-small cell lung carcinomas (NSCLC). However, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has decreased the tissue available for these assessments. While EBUS-TBNA specimens have previously been reported to successfully subtype NSCLC, allow immunohistochemistry (IHC), and support molecular diagnostics, no studies have documented the extent to which all objectives are possible in a single sample. Of 107 consecutive EBUS-TBNA specimens that were eligible for molecular testing, 98.8{\%} had enough tissue for IHC, 80.2{\%} received a definitive subtype, and 71.0{\%} had both sufficient tissue to attempt molecular testing and technical success on multigene next-generation sequencing and ALK fluorescence in situ hybridization assays. Both subtyping and molecular diagnostics were possible in 57.9{\%} of patients. The mean number of immunostains performed did not differ between patients with or without successful molecular testing (4.4 versus 4.6, P =.88). Only 40{\%} of patients with insufficient tissue underwent repeat sampling. These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC, performing IHC, and completing multiple gene analyses. Although priorities must be assessed for each case individually, performance of IHC does not detract from completion of molecular diagnostics in general. Because most patients never undergo repeat sampling, the tissue yield of EBUS-TBNA should be improved to maximize evaluation for targeted therapies.",
keywords = "Adequacy, Cytology, EBUS-TBNA, Immunohistochemistry, Molecular diagnostics, Non-small cell lung cancer",
author = "Rooper, {Lisa M.} and Olga Nikolskaia and Carter, {Jamal H.} and Yi Ning and Lin, {Ming Tseh} and Zahra Maleki",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.humpath.2015.12.025",
language = "English (US)",
volume = "51",
pages = "139--145",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non-small cell lung cancer cases

AU - Rooper, Lisa M.

AU - Nikolskaia, Olga

AU - Carter, Jamal H.

AU - Ning, Yi

AU - Lin, Ming Tseh

AU - Maleki, Zahra

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Summary Targeted therapies for pulmonary adenocarcinoma (ACA) necessitate specific subtyping and molecular testing of non-small cell lung carcinomas (NSCLC). However, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has decreased the tissue available for these assessments. While EBUS-TBNA specimens have previously been reported to successfully subtype NSCLC, allow immunohistochemistry (IHC), and support molecular diagnostics, no studies have documented the extent to which all objectives are possible in a single sample. Of 107 consecutive EBUS-TBNA specimens that were eligible for molecular testing, 98.8% had enough tissue for IHC, 80.2% received a definitive subtype, and 71.0% had both sufficient tissue to attempt molecular testing and technical success on multigene next-generation sequencing and ALK fluorescence in situ hybridization assays. Both subtyping and molecular diagnostics were possible in 57.9% of patients. The mean number of immunostains performed did not differ between patients with or without successful molecular testing (4.4 versus 4.6, P =.88). Only 40% of patients with insufficient tissue underwent repeat sampling. These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC, performing IHC, and completing multiple gene analyses. Although priorities must be assessed for each case individually, performance of IHC does not detract from completion of molecular diagnostics in general. Because most patients never undergo repeat sampling, the tissue yield of EBUS-TBNA should be improved to maximize evaluation for targeted therapies.

AB - Summary Targeted therapies for pulmonary adenocarcinoma (ACA) necessitate specific subtyping and molecular testing of non-small cell lung carcinomas (NSCLC). However, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has decreased the tissue available for these assessments. While EBUS-TBNA specimens have previously been reported to successfully subtype NSCLC, allow immunohistochemistry (IHC), and support molecular diagnostics, no studies have documented the extent to which all objectives are possible in a single sample. Of 107 consecutive EBUS-TBNA specimens that were eligible for molecular testing, 98.8% had enough tissue for IHC, 80.2% received a definitive subtype, and 71.0% had both sufficient tissue to attempt molecular testing and technical success on multigene next-generation sequencing and ALK fluorescence in situ hybridization assays. Both subtyping and molecular diagnostics were possible in 57.9% of patients. The mean number of immunostains performed did not differ between patients with or without successful molecular testing (4.4 versus 4.6, P =.88). Only 40% of patients with insufficient tissue underwent repeat sampling. These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC, performing IHC, and completing multiple gene analyses. Although priorities must be assessed for each case individually, performance of IHC does not detract from completion of molecular diagnostics in general. Because most patients never undergo repeat sampling, the tissue yield of EBUS-TBNA should be improved to maximize evaluation for targeted therapies.

KW - Adequacy

KW - Cytology

KW - EBUS-TBNA

KW - Immunohistochemistry

KW - Molecular diagnostics

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84961139439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961139439&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2015.12.025

DO - 10.1016/j.humpath.2015.12.025

M3 - Article

C2 - 26980023

AN - SCOPUS:84961139439

VL - 51

SP - 139

EP - 145

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -